The Effect of Somatostatin on the Rise of Growth Hormone and Glucagon Secretion Induced by Arginine and L-Dopa in Diabetic Patients

References

• Alberti K. G. M. M., Christensen N. J., Christensen S. E., Hansen Aa. P., Iversen J., Lundbaek K., Seyer-Hansen K., Örskov H. Inhibition of insulin secretion by somatostatin. Lancet 1973; 2: 1299
   PubMed Web of Science ®Google Scholar
• Besser G. M., Mortimer C. H., Carr D., Schally A. V., Coy D. H., Evered D., Kastin A. J., Tunbridge W. M. G., Thorner M. O., Hall R. Growth hormone release inhibiting hormone in acromegaly. Brit. med. J. 1974; 1: 352
   PubMed Web of Science ®Google Scholar
• Brazeau P., Guillemin R. Somatostatin: newcomer from the hypothalamus. N. Engl. J. Med. 1974; 290: 963
   PubMedGoogle Scholar
• Brazeau P., Rivier J., Vale W., Guillemin R. Inhibition of growth hormone secretion in the rat by synthetic somatostatin. Endocrinology 1974; 94: 184
   PubMed Web of Science ®Google Scholar
• Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77
   PubMed Web of Science ®Google Scholar
• Christensen N. J. Notes on the glucose oxidase method. Scand. J. clin. Lab. Invest. 1967; 19: 379
   PubMed Web of Science ®Google Scholar
• Christensen S. E., Hansen Aa. P., Iversen J., Lundbaek K., Örskov H., Seyer-Hansen K. Somatostatin as a tool in studies of basal carbohydrate and lipid metabolism in man: modifications of glucagon and insulin release. Scand. J. clin. Lab. Invest. 1974; 34: 321
   PubMed Web of Science ®Google Scholar
• Cremer G. M., Molnar G. D., Taylor W. F., Moxness K. E., Service F. J., Gatewood L. C, Ackerman E., Rosevear J. W. Test of insulinogenic reserve with infusions of arginine, glucagon, epinephrine and saline. Metabolism 1971; 20: 1083
   Google Scholar
• DeVane G. W., Siler T. M., Yen S. S. C. Acute suppression of insulin and glucose levels by synthetic somatostatin in normal human subjects. J. clin. Endocr. 1974; 38: 913
   Google Scholar
• Grant N., Personal communication
   Google Scholar
• Hall R., Besser G. M., Schally A. V., Coy D. H., Evered D., Goldie D. L., Kastin A. L., McNeilly A. S., Mortimer C. H., Phenekos C., Tunbridge W. M. G., Weightman D. Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet 1973; 2: 7829
   Google Scholar
• Hansen Aa. P. Serum growth hormone patterns in juvenile diabetes (thesis). Dan. med. Bull. 1972; 1, Suppl. 1
   Google Scholar
• Hansen Aa. P., Örskov H., Seyer-Hansen K., Lundbaek K. Some actions of growth hormone release inhibiting factor. Brit. med. J. 1973; 3: 523
   PubMed Web of Science ®Google Scholar
• Heding L. G. Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia 1971; 7: 10
   PubMed Web of Science ®Google Scholar
• Ho R. J., Meng H. C. A simple and ultrasensitive method for determination of free fatty acid by radiochemical assay. Analyt. Biochem. 1969; 31: 426
   PubMed Web of Science ®Google Scholar
• Iversen J. Inhibition of pancreatic glucagon release by somatostatin: in vitro. Scand. J. clin. Lab. Invest. 1974; 33: 125
   PubMed Web of Science ®Google Scholar
• Koerker D. J., Ruch W., Chideckel E., Palmer J., Goodner C. J., Ensinck J., Gale C. Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 1974; 184: 482
   PubMed Web of Science ®Google Scholar
• Lundbaek K., Christensen N. J., Jensen V. A., Johansen K., Olsen T. S., Hansen Aa. P., Örskov H., Österby R. Diabetes, diabetic angiopathy, and growth hormone. Lancet 1970; 2: 131
   PubMed Web of Science ®Google Scholar
• Mortimer C. H., Tunbridge W. M. G., Carr D., Yeomans L., Lind T., Coy D. H., Bloom S. R., Kastin A., Mallinson C. N., Besser G. M., Schally A. V., Hall R. Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet 1974; 1: 697
   PubMed Web of Science ®Google Scholar
• Örskov H., Thomsen H. G., Yde H. Wick chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature (Lond.) 1968; 219: 193
   PubMed Web of Science ®Google Scholar
• Parker D. C, Rossman L. G., Siler T. M., Rivier J., Yen S. S. C., Guillemin R. Inhibition of the sleep-related peak in physiologic human growth hormone release by somatostatin. J. clin. Endocr. 1974; 38: 496
   PubMedGoogle Scholar
• Rivera-Calimlom L., Bianchine J. R. Effect of 1-dopa on plasma free fatty acids and plasma glucose. Metabolism 1972; 21: 611
   Google Scholar
• Sarantakis D., McKinley W. A. Total synthesis of hypothalamic ‘somatostatin’. Biochem. biophys. Res. Commun. 1973; 54: 234
   PubMed Web of Science ®Google Scholar
• Siler T. M., Vanden Berg G., Yen S. S.C., Brazeau P., Vale W., Guillemin R. Inhibition of growth hormone release in humans by somatostatin. J. clin. Endocr. 1973; 37: 632
   PubMed Web of Science ®Google Scholar
• Siler T. M., Yen S. S.C., Vale W., Guillemin R. Inhibition by somatostatin on the release of TSH induced in man by thyrotropinreleasing factor. J. clin. Endocr. 1974; 38: 742
   PubMed Web of Science ®Google Scholar
• Thomsen H. G. Pancreatic glucagon and ‘glucagon-like’ material in the blood. Diabetologia 1969; 5: 430
   Web of Science ®Google Scholar
• Unger R. H. Glucagon and the insulin: glucagan ratio in diabetes and other catabolic illnesses. Diabetes 1971; 20: 834
   PubMed Web of Science ®Google Scholar
• Weeke J., Hansen Aa. P., Lundbæk K. The inhibition by somatostatin of the thyrotropin response to thyrotropin-releasing hormone in normal subjects. Scand. J. clin. Lab. Invest. 1974; 33: 101
   PubMed Web of Science ®Google Scholar
• Yen S. S.C., Siler T. M., DeVane G. W. Effects of somatostatin in patients with acromegaly. N. Engl. J. Med. 1974; 290: 935
   PubMed Web of Science ®Google Scholar